Novo Nordisk In Recovery Mode After Earlier Sell-Off
Novo Nordisk (NVO) is recovering after falling earlier this month on bad news from U.S. regulators. On Nov. 6, the drugmaker slumped 9% after the Food & Drug Administration warned of potential heart problems in its long-lasting insulin degludec. Since then, an FDA advisory panel has backed degludec and the company is now waiting for the agency's approval. The stock is back near levels where it fell earlier. But it's now grappling with upside
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here